Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Cancer. 2020 Nov 1;126(21):4630-4633. doi: 10.1002/cncr.33125. Epub 2020 Aug 14.
The evaluation and management of patients with cancer with suspected immune checkpoint inhibitor (ICI) colitis have distinct challenges within the setting of the coronavirus disease 2019 (COVID‐19) pandemic. The approach to the treatment of patients with ICI colitis requires consideration of the risks and benefits of individual immunosuppressive medications and varies based on the presence of a concurrent COVID‐19 infection.
在 2019 冠状病毒病（COVID-19）大流行背景下，疑似免疫检查点抑制剂（ICI）结肠炎的癌症患者的评估和管理具有独特的挑战。ICI 结肠炎患者的治疗方法需要考虑个体免疫抑制药物的风险和获益，并根据是否存在同时感染 COVID-19 而有所不同。
